In this online, self-learning activity:
Neonatal respiratory distress syndrome (RDS) occurs in an estimated five to seven percent of term births and up to 90% of preterm births. The risk for neonatal RDS decreases with increasing gestational age, such that at a gestational age of 37 weeks, the risk has fallen to just three times that of a full-term infant. In addition to premature birth, risk factors for neonatal RDS include maternal gestational diabetes, male sex, multiparity, abnormal fetoplacental circulation, fetal distress, Cesarean delivery, and low birth weight. The ability for the clinician to recognize neonatal RDS is a documented practice gap, and failure to do so is associated with mortality and complications that may include respiratory failure in the short-term and chronic lung disease in the long-term.
The following healthcare professionals: neonatologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in neonatology; and any other healthcare professionals with an interest in or who clinically encounter patients with neonatal RDS.
Commercial Support Disclosure: This program is supported by an educational grant from Chiesi USA.
This activity is free of charge.
Release Date: April 26, 2023 -- Expiration Date: April 26, 2025
Faculty: Rangasamy Ramanathan, MD
Faculty introduction, disclosures |
Introduction content: cursory refresher and review of neonatal RDS
|
Neonatal RDS treatment
|
Summary, conclusions, and best practice recap |
By the end of the session the participant will be able to:
ACCME Activity #202470464
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved through content review by ScientiaCME.
Disclosure of Faculty: Rangasamy Ramanathan, MD, Professor of Pediatrics, Keck School of Medicine of USC, has received financial compensation for consulting and research from Chiesi USA and Chiesi Framaceutici (Italy).
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL NOT discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Chiesi USA.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Primary immunodeficiency disorders (PIDD): Present management and ongoing needs